Omnicell/$OMCL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Omnicell

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Ticker

$OMCL
Sector
Primary listing

Employees

3,650

Omnicell Metrics

BasicAdvanced
$1.4B
62.80
$0.49
0.82
-

What the Analysts think about Omnicell

Analyst ratings (Buy, Hold, Sell) for Omnicell stock.

Bulls say / Bears say

Recurring revenue now represents 56% of total revenue in Q1 2025, reducing dependence on one-time device sales and improving revenue predictability. (Investing.com)
Total revenues in Q1 2025 rose 10% YoY to $270 million, and non-GAAP net income increased to $12 million (EPS $0.26), driven by strong growth in the XT Amplify program and SaaS and Expert Services. (Omnicell IR)
Management authorized a new $75 million stock repurchase program and benefited from a temporary U.S. tariff reduction on Chinese imports from 145% to 30%, reflecting confidence in free cash flow and lowering near-term cost pressures. (RTTNews)
Tariff headwinds are expected to weigh on profitability, with management forecasting a $40 million annual non-GAAP EBITDA impact from Chinese import tariffs and widening profit guidance ranges. (Ainvest)
In Q2 2025, non-GAAP EBITDA declined 4% YoY to $38 million and non-GAAP EPS fell to $0.45, indicating margin pressure despite revenue growth. (Investing.com)
Connected devices and software licenses revenue for full year 2025 is projected to grow less than 1% YoY ($625 million–$640 million vs prior year), highlighting a slowdown in equipment sales amid the XT Series replacement cycle. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Omnicell Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Omnicell Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OMCL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs